Gapping up
In reaction to strong earnings/guidance: CGA +27.1%, MAS +4%, UMC +3.7%, L +2.6%, NAVB +2.4%, NSSC +2.4%, CBZ +1.8%, NRG +1.7%, HAS +1.5%, MPAA +1.4%, GOLD +1.1%, ONVO +0.8%, CCJ +0.5%, IPGP +0.5%
M&A news: MSI +4.4% (considering possible sale, according to reports)
Select metals/mining stocks trading higher: GFI +1.8%, SLV +1.1%, BHP +1%, EGO +0.8%, ABX +0.7%, RIO +0.7%, GG +0.6%
Select oil/gas related names showing strength: STO +3.6%, LINE +2.5%, WLL +2.1%, RIG +1.6%, KEG +1.5%, EPE +1.5%, BP +0.8%
Other news: ATOS +34.5% (signs national distribution agreement with Thermo Fisher (TMO) for FullCYTE Breast Aspirator), ACHN +14% (announces updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate ACH-3102 and 400 mg of sofosbuvir), ONCY +9.5% (submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration for REOLYSIN), NQ +5.1% (light volume, still checking), ATU +4.9% (positive Barron's mention), CGEN +4.1% (announces new results supporting CGEN-15049 as potential cancer immunotherapy target), CJES +2.9% (reached an agreement with Nabors Industries Ltd. (NBR) to reduce by $250 mln), TNH +2.5% (declares quarterly distribution of $2.50 per unit vs. $1.78 in the prior quarter), PVCT +2.5% (held a Type C meeting with the FDA to review certain operational aspects of the protocol for its planned phase 3 clinical trial of intralesional PV-10 as a treatment for melanoma), OCN +2.5% (cont strength), QCOM +2.3% (close to agreeing to pay $1 bln China antitrust fine, according to reports), YNDX +2% (still checking, hearing may be attributed to undisclosed overseas coverage with Buy initiation)
Analyst comments: CONN +4% (upgraded to Buy from Hold at Stifel), STO +3.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley), NVS +2.5% (resumed with a Buy at Citigroup), INSY +2.1% (target raised to $63 from $51 at Jefferies), HABT +2.1% (initiated with a Buy at Longbow), MOS +1.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
In reaction to strong earnings/guidance: CGA +27.1%, MAS +4%, UMC +3.7%, L +2.6%, NAVB +2.4%, NSSC +2.4%, CBZ +1.8%, NRG +1.7%, HAS +1.5%, MPAA +1.4%, GOLD +1.1%, ONVO +0.8%, CCJ +0.5%, IPGP +0.5%
M&A news: MSI +4.4% (considering possible sale, according to reports)
Select metals/mining stocks trading higher: GFI +1.8%, SLV +1.1%, BHP +1%, EGO +0.8%, ABX +0.7%, RIO +0.7%, GG +0.6%
Select oil/gas related names showing strength: STO +3.6%, LINE +2.5%, WLL +2.1%, RIG +1.6%, KEG +1.5%, EPE +1.5%, BP +0.8%
Other news: ATOS +34.5% (signs national distribution agreement with Thermo Fisher (TMO) for FullCYTE Breast Aspirator), ACHN +14% (announces updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate ACH-3102 and 400 mg of sofosbuvir), ONCY +9.5% (submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration for REOLYSIN), NQ +5.1% (light volume, still checking), ATU +4.9% (positive Barron's mention), CGEN +4.1% (announces new results supporting CGEN-15049 as potential cancer immunotherapy target), CJES +2.9% (reached an agreement with Nabors Industries Ltd. (NBR) to reduce by $250 mln), TNH +2.5% (declares quarterly distribution of $2.50 per unit vs. $1.78 in the prior quarter), PVCT +2.5% (held a Type C meeting with the FDA to review certain operational aspects of the protocol for its planned phase 3 clinical trial of intralesional PV-10 as a treatment for melanoma), OCN +2.5% (cont strength), QCOM +2.3% (close to agreeing to pay $1 bln China antitrust fine, according to reports), YNDX +2% (still checking, hearing may be attributed to undisclosed overseas coverage with Buy initiation)
Analyst comments: CONN +4% (upgraded to Buy from Hold at Stifel), STO +3.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley), NVS +2.5% (resumed with a Buy at Citigroup), INSY +2.1% (target raised to $63 from $51 at Jefferies), HABT +2.1% (initiated with a Buy at Longbow), MOS +1.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley)